ClinicalTrials.gg
Active, not recruitingNCT05640908PAULAUpdated Jan 23, 2026

Pelvic Fixation and Fusion During Multilevel Spinal Surgery

An observational study in Spinal Fusion and Deformity of Spine, sponsored by SI-BONE, Inc.. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by SI-BONE, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

PAULA aims to collect data on the safety, performance, and effectiveness of iFuse Bedrock Granite (GRANITE) in patients who have spinal fusion surgery with pelvic fixation/ fusion.

Read the detailed description

PAULA is a multicenter, open label, single-arm observational clinical study consisting of prospective and retrospective study cohorts. The goal of the study is to collect data on the safety, performance, and effectiveness of GRANITE.

02

Conditions studied

  • Spinal Fusion
  • Deformity of Spine
03

In context

Lead sponsor

SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with spinal fusion including pelvic fixation/fusion using GRANITE

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age at screening.
  2. Patient is scheduled for spinal fusion with pelvic fixation/fusion using iFuse Bedrock Granite
  3. Patient is willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Any known anatomic issues or permanent implants already in the pelvis that could interfere with placement of the study device(s)
  2. Prominent neurologic or uncontrolled psychiatric condition that would interfere with study participation
  3. Known allergy to titanium or titanium alloys
  4. Current local or systemic infection that raises the risk of surgery
  5. Currently pregnant or planning pregnancy in the next 2 years
  6. Known or suspected active drug or alcohol abuse, including opioids
  7. Patient is a prisoner or ward of the state
  8. Patient is enrolled in an clinical trial related to the spine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective

    Participants who have scheduled spinal fusion with pelvic fixation/fusion using iFuse Bedrock Granite. These participants will be followed for 2 years.

    Device: iFuse Bedrock Granite Implant System

Interventions

  • DeviceiFuse Bedrock Granite Implant System

    Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite

    Also known as: GRANITE, Bedrock Granite

06

What researchers measure

Primary outcomes

  1. Postoperative incidence of serious adverse events probably or definitely related to GRANITE

    Time frame: 2 years

  2. Postoperative incidence of SI joint pain in subject without SI joint pain at baseline

    Time frame: 2 years

  3. Postoperative incidence of L5-S1 pseudoarthrosis

    Time frame: 2 years

  4. Postoperative incidence of pelvic construct failure

    Failure is defined as: * Breakage of any implants placed into sacrum or ilium * Rod breakage in the lumbosacral region * Pelvic implant loosening that either causes new or worsened pain or requires surgical adjustment/revision

    Time frame: 2 years

  5. Postoperative incidence of device failures related to GRANITE (e.g., rod disengagement, screw pullout)

    Time frame: 2 years

  6. Radiographic

    Bony apposition to the implant at 12 and 24 months as assessed by CT scan

    Time frame: 12 month and 24 months

  7. Change in Quality of Life PROs

    Scores on PROs at follow up timepoints compared to baseline

    Time frame: 6 month, 12 month and 24 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Nov 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 7, 2022
StartActual
Jun 5, 2023
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05640908
Lead sponsor
SI-BONE, Inc.
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Jun 5, 2023
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Robyn Capobianco, PhD
study director · SI-BONE, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion